Latest Abcuro News & Updates

See the latest news and media coverage for Abcuro. We track all announcements, press releases, and industry mentions in real time, all in one place.

Abcuro

Biotechnology company developing antibody therapies for autoimmune diseases and cancer

abcuro.com

Company type: Private company
Number of employees: 50–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Abcuro

In short: Abcuro secured $66 million in Series D funding and reported Phase 2/3 trial results for ulviprubart in inclusion body myositis.

Company announcements

April 19 Abcuro

Abcuro presents Phase 2/3 ulviprubart study topline results

The study covers design, patient characteristics, and results for inclusion body myositis. Published April 19, 2026.

April 3 Abcuro

Abcuro presents phase 2/3 ulviprubart study results

Study misses primary IBMFRS endpoint but shows trends of slowed progression in less severe patients. Ulviprubart depletes target T cells with favorable safety.

March 26 Abcuro

Abcuro presents topline results of ulviprubart Phase 2/3 study

The study focuses on inclusion body myositis, covering design, patient characteristics, and results.

February 24 Abcuro

Abcuro announces topline results from MUSCLE study

Phase 2/3 study misses primary endpoints but shows trends in mild-moderate IBM patients and favorable safety. Results to be presented at GCOM.

Media coverage

August 14 MedCity News

Abcuro Adds $66M to Try Again in Rare Inflammatory Disorder With No Approved Drugs

Immunotherapy developer Abcuro received disappointing news this year as its lead drug candidate fell short in a clinical trial expected to support a regulatory submission...

March 26 BioSpace

Abcuro Presents Results from Phase 2/3 MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis at GCOM 2026 - BioSpace

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26...

March 11 Targeted Oncology

Phase 1/2 Study of ABC008 in T-Cell Large Granular Lymphocytic Leukemia Commences | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Sponsor: Abcuro, Inc.

March 4 Rheumatology Advisor

Ulviprubart Fails to Meet Endpoints in Inclusion Body Myositis Study

Topline results from the MUSCLE study indicate that ulviprubart did not meet its primary endpoint of mean change in inclusion body myositis functional rating scale...

Never miss news about Abcuro

Track Abcuro and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Abcuro competitors & trending companies

Browse news for competitors to Abcuro and other trending companies.